Smirnova N G, Chefu S G, Kovalenko A L, Vlasov T D
Eksp Klin Farmakol. 2010 Sep;73(9):24-7.
Remaxol is a new infusion hepatoprotector that contains succinic acid, inosine, methionine and methylglucamine. The hepatoprotective effect of remaxol on the liver function has been studied on the model of obstructive jaundice in rats, on the terms of one and two weeks after ligation of the common bile duct (M. A. Aller, et al., 2004). Sixty rats were randomly divided into six groups: sham-operated rats with cholestasis, 0.9% NaCl treated rats with cholestasis, and remaxol treated rats with cholestasis, all on the one week (per os n=10) and two weeks (n=10) terms. Remaxol was injected into the tail vein in a dose of 1 ml/100 g during the first week after the induction of cholestasis. The rats were removed from the experiment after one and two weeks of postoperative period, respectively. The size and weight of the liver and the degree of ascites were measured, and the blood samples were taken to analyze for bilirubin, alkaline phosphatase, gamma-glutamyl transpeptidase, alanineaminotransferase, aspartataminotransferase. Morphological changes in the liver were also studied. The biochemical parameters of blood and morphological evolution of tissue of liver in both one and two weeks after the induction of cholestasis showed a significant hepatoprotective effect of remaxol.
瑞美索（Remaxol）是一种新型的静脉注射用肝保护剂，含有琥珀酸、肌苷、蛋氨酸和葡甲胺。瑞美索对肝功能的肝保护作用已在大鼠阻塞性黄疸模型上进行了研究，即在胆总管结扎术后1周和2周的条件下（M. A. 阿勒等人，2004年）。60只大鼠被随机分为6组：假手术致胆汁淤积的大鼠、用0.9%氯化钠治疗的胆汁淤积大鼠以及用瑞美索治疗的胆汁淤积大鼠，每组均分为术后1周（经口给药，n = 10）和2周（n = 10）两个时间段。在胆汁淤积诱导后的第一周，以1 ml/100 g的剂量将瑞美索注入大鼠尾静脉。分别在术后1周和2周将大鼠从实验中取出。测量肝脏的大小和重量以及腹水程度，并采集血样分析胆红素、碱性磷酸酶、γ-谷氨酰转肽酶、丙氨酸转氨酶、天冬氨酸转氨酶。还研究了肝脏的形态学变化。胆汁淤积诱导后1周和2周时血液的生化参数以及肝脏组织的形态学演变均显示瑞美索具有显著的肝保护作用。
